Literature DB >> 21084995

Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire.

Didier K Ekouevi1, Patrick A Coffie, Eric Ouattara, Raoul Moh, Clarisse Amani-Bosse, Eugene Messou, Marcel Sissoko, Xavier Anglaret, Serge P Eholié, Christine Danel, François Dabis.   

Abstract

BACKGROUND: An increasing number of HIV-infected women become pregnant while receiving efavirenz (EFV). We compared the pregnancy outcomes of women exposed to EFV and to nevirapine (NVP) during the first trimester.
METHODS: A retrospective study in 4 HIV care centers participating to clinical trials and international cohort collaboration. All HIV-infected pregnant women who conceived on EFV-based or NVP-based antiretroviral therapy (ART) between 2003 and 2009 were included. Pregnancy outcomes were as follows: abortion (voluntary termination), miscarriage [unwanted termination <20 weeks of amenorrhea (WA)], stillborn (death ≥ 20 WA), preterm delivery (live-birth <37 WA), and low birth weight (LBW) (<2500 grams).
RESULTS: Overall, 344 HIV-infected pregnant women conceived on ART (213 on EFV and 131 on NVP). Median age was 29 years, and median CD4 count 217 cells per microliter at ART initiation. The overall proportion was 11.7% for abortion, 5.2% for miscarriage, 6.7% for stillborn, 10.8% for preterm delivery, and 20.2% for LBW. There was no difference between EFV and NVP exposure, except for abortion (14.3% vs 7.3%; P = 0.05). No external and visible congenital malformation was observed neither in women exposed to EFV nor in women exposed to NVP.
CONCLUSIONS: Among women exposed to EFV, no significant increased risk of unfavorable pregnancy outcome was reported except for abortion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21084995      PMCID: PMC3045727          DOI: 10.1097/QAI.0b013e3181ff04e6

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  16 in total

1.  Myelomeningocele in a child with intrauterine exposure to efavirenz.

Authors:  Carlo Fundarò; Orazio Genovese; Claudia Rendeli; Enrica Tamburrini; Elio Salvaggio
Journal:  AIDS       Date:  2002-01-25       Impact factor: 4.177

2.  Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women?

Authors:  Deven Patel; Claire Thorne; Simona Fiore; Marie-Louise Newell
Journal:  J Acquir Immune Defic Syndr       Date:  2005-09-01       Impact factor: 3.731

3.  Quantifying antiretroviral risk in pregnancy.

Authors:  Theresa Rossouw
Journal:  S Afr Med J       Date:  2007-11

4.  [Efavirenz (Sustiva) in pregnancy: a study about 12 HIV patients].

Authors:  V Jeantils; M-A Khuong; J-L Delassus; P Honoré; B Taverne; M Uzan; S Tassi
Journal:  Gynecol Obstet Fertil       Date:  2006-06-30

5.  Myelomeningocele in an infant with intrauterine exposure to efavirenz.

Authors:  Akihiko Saitoh; Andrew D Hull; Patricia Franklin; Stephen A Spector
Journal:  J Perinatol       Date:  2005-08       Impact factor: 2.521

6.  Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa.

Authors:  Christine Danel; Raoul Moh; Amani Anzian; Yao Abo; Henri Chenal; Calixte Guehi; Delphine Gabillard; Souleymane Sorho; François Rouet; Serge Eholié; Xavier Anglaret
Journal:  J Acquir Immune Defic Syndr       Date:  2006-05       Impact factor: 3.731

7.  Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.

Authors:  Alexandra Calmy; Lorextu Pinoges; Elisabeth Szumilin; Rony Zachariah; Nathan Ford; Laurent Ferradini
Journal:  AIDS       Date:  2006-05-12       Impact factor: 4.177

8.  Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana.

Authors:  Hermann Bussmann; C William Wester; Carolyn N Wester; Bright Lekoko; Okechukwu Okezie; Ann Muir Thomas; S M Victor DeGruttola; Joseph Makhema; Max Essex; Richard G Marlink
Journal:  J Acquir Immune Defic Syndr       Date:  2007-07-01       Impact factor: 3.731

9.  [Time trends in demographic and clinical characteristics of adult patients on HAART initiation in West Africa].

Authors:  J Bashi; E Balestre; E Messou; M Maiga; P A Coffie; D M Zannou; O Ba-Gomis; H A Traore; S Eholie; A Minga; P S Sow; E Bissagnene; F Dabis; D K Ekouevi
Journal:  Med Mal Infect       Date:  2009-12-31       Impact factor: 2.152

10.  Pregnancy outcomes and antiretroviral treatment in a national cohort of pregnant women with HIV: overall rates and differences according to nationality.

Authors:  M Floridia; E Tamburrini; A Bucceri; C Tibaldi; G Anzidei; G Guaraldi; A Meloni; B Guerra; E Ferrazzi; A Molinari; C Pinnetti; B Salerio; M Ravizza
Journal:  BJOG       Date:  2007-05-15       Impact factor: 6.531

View more
  17 in total

1.  Pregnancy outcomes in women with advanced HIV infection in Italy.

Authors:  Silvia Baroncelli; Enrica Tamburrini; Marina Ravizza; Carmela Pinnetti; Serena Dalzero; Manuela Scatà; Alessandra Crepaldi; Giuseppina Liuzzi; Atim Molinari; Antonella Vimercati; Anna Maccabruni; Daniela Francisci; Elena Rubino; Marco Floridia
Journal:  AIDS Patient Care STDS       Date:  2011-09-23       Impact factor: 5.078

2.  Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.

Authors:  Rebecca Zash; Denise L Jacobson; Modiegi Diseko; Gloria Mayondi; Mompati Mmalane; Max Essex; Chipo Petlo; Shahin Lockman; Joseph Makhema; Roger L Shapiro
Journal:  JAMA Pediatr       Date:  2017-10-02       Impact factor: 16.193

3.  Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.

Authors:  Eric N Ouattara; Xavier Anglaret; Angela Y Wong; Jennifer Chu; Heather E Hsu; Christine Danel; Serge Eholié; Raoul Moh; Delphine Gabillard; Rochelle P Walensky; Kenneth A Freedberg
Journal:  AIDS       Date:  2012-03-13       Impact factor: 4.177

4.  Human Immunodeficiency Virus Infection Is Associated With Preterm Delivery Independent of Vaginal Microbiota in Pregnant African Women.

Authors:  Muchaneta Gudza-Mugabe; Enock Havyarimana; Shameem Jaumdally; Kirsty Lee Garson; Katie Lennard; Andrew Tarupiwa; Fortunate Mugabe; Tarisai Marere; Rooyen T Mavenyengwa; Lindi Masson; Heather B Jaspan
Journal:  J Infect Dis       Date:  2020-03-16       Impact factor: 5.226

Review 5.  Complex decisions in managing HIV infection during pregnancy.

Authors:  Mary A Vogler; Harjot Singh; Rodney Wright
Journal:  Curr HIV/AIDS Rep       Date:  2011-06       Impact factor: 5.071

6.  Is tenofovir/emtricitabine teratogenic?

Authors:  Murtala Jibril; Oluwaseun Egunsola
Journal:  Ther Adv Drug Saf       Date:  2013-06

7.  Adverse Pregnancy Outcomes Among Women Who Conceive on Antiretroviral Therapy.

Authors:  Risa M Hoffman; Sean S Brummel; Paula Britto; Jose H Pilotto; Gaerolwe Masheto; Linda Aurpibul; Esau Joao; Murli U Purswani; Shelley Buschur; Marie Flore Pierre; Anne Coletti; Nahida Chakhtoura; Karin L Klingman; Judith S Currier
Journal:  Clin Infect Dis       Date:  2019-01-07       Impact factor: 9.079

8.  Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception.

Authors:  Susie E Huntington; Loveleen K Bansi; Claire Thorne; Jane Anderson; Marie-Louise Newell; Graham P Taylor; Deenan Pillay; Teresa Hill; Pat A Tookey; Caroline A Sabin
Journal:  AIDS       Date:  2011-08-24       Impact factor: 4.177

Review 9.  HIV treatment and care in resource-constrained environments: challenges for the next decade.

Authors:  Serge-Paul Eholié; François Eba Aoussi; Ismael Songda Ouattara; Emmanuel Bissagnéné; Xavier Anglaret
Journal:  J Int AIDS Soc       Date:  2012-08-22       Impact factor: 5.396

10.  Antiretroviral therapy, pregnancy, and birth defects: a discussion on the updated data.

Authors:  Luiz Euribel Prestes-Carneiro
Journal:  HIV AIDS (Auckl)       Date:  2013-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.